/Investor DB

The Column Group — 2016 Investments

2 investments dated 2016 · listed companies and verified rows first · show all

Revolution Medicinesrevmed.cominNASDAQ: RVMDSeries A · Dec 2016 · $25M

Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.

BiotechHealthtechMedical DevicesRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Co-investorsBain Capital Life SciencesForesite CapitalGen CapitalGV (Google Ventures)Illinois VenturesNextech Invest+2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

FLX Bio

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.